Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1172 ARTÍCULOS , VIENDO DEL 976 AL 990

Nuclear medicine diagnostic techniques in the era of pathophysiology-based CSF biomarkers for Alzheimer's disease

Weih M, Degirmenci U, Kreil S, Suttner G, Schmidt D, Kornhuber J, Lewczuk P, Kuwert T.

J Alzheimers Dis. 2011;26 Suppl 3:97-103. doi: 10.3233/JAD-2011-0020.

Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage

Drago V, Babiloni C, Bartrés-Faz D, Caroli A, Bosch B, Hensch T, Didic M, Klafki HW, Pievani M, Jovicich J, Venturi L, Spitzer P, Vecchio F, Schoenknecht P, Wiltfang J, Redolfi A, Forloni G, Blin O, Irving E, Davis C, Hårdemark HG, Frisoni GB.

J Alzheimers Dis. 2011;26 Suppl 3:159-99. doi: 10.3233/JAD-2011-0043.

Searching for novel biomarkers using high resolution diffusion tensor imaging

Yassa MA.

J Alzheimers Dis. 2011;26 Suppl 3(Suppl 3):297-305. doi: 10.3233/JAD-2011-0005.

Fluorodeoxyglucose positron emission tomography: emerging roles in the evaluation of putative Alzheimer's disease-modifying treatments

Reiman EM; Alzheimer's Disease Biomarkers Working Group for the Alliance for Aging Research.

Neurobiol Aging. 2011 Dec;32 Suppl 1(Suppl 1):S44-7. doi: 10.1016/j.neurobiolaging.2011.09.007. Epub 2011 Oct 7.

Clinical trial methodologies for disease-modifying therapeutic approaches

Aisen PS.

Neurobiol Aging. 2011 Dec;32 Suppl 1(Suppl 1):S64-6. doi: 10.1016/j.neurobiolaging.2011.09.008. Epub 2011 Oct 8.

Aβ-degrading enzymes: potential for treatment of Alzheimer disease

Miners JS, Barua N, Kehoe PG, Gill S, Love S.

J Neuropathol Exp Neurol. 2011 Nov;70(11):944-59. doi: 10.1097/NEN.0b013e3182345e46.

Circulating biomarkers of protein oxidation for Alzheimer disease: expectations within limits

Di Domenico F, Coccia R, Butterfield DA, Perluigi M.

Biochim Biophys Acta. 2011 Dec;1814(12):1785-95. doi: 10.1016/j.bbapap.2011.10.001. Epub 2011 Oct 12.

Challenges in the development of companion diagnostics for neuropsychiatric disorders

Nikolcheva T, Jäger S, Bush TA, Vargas G.

Expert Rev Mol Diagn. 2011 Nov;11(8):829-37. doi: 10.1586/erm.11.67.

The role of reelin gene polymorphisms in the pathogenesis of Alzheimer's disease in a Greek population

Antoniades D, Katopodi T, Pappa S, Lampropoulos A, Konsta V, Frydas E, Mpalogiannis S, Hatzistilianou M.

J Biol Regul Homeost Agents. 2011 Jul-Sep;25(3):351-8.

Shift in brain metabolism in late onset Alzheimer's disease: implications for biomarkers and therapeutic interventions

Yao J, Rettberg JR, Klosinski LP, Cadenas E, Brinton RD.

Mol Aspects Med. 2011 Aug;32(4-6):247-57. doi: 10.1016/j.mam.2011.10.005. Epub 2011 Oct 21.

Risk-takers wanted

Nat Med. 2011 Nov 7;17(11):1321. doi: 10.1038/nm.2573.

Evolution of the diagnostic criteria for degenerative and cognitive disorders

Lopez OL, McDade E, Riverol M, Becker JT.

Curr Opin Neurol. 2011 Dec;24(6):532-41. doi: 10.1097/WCO.0b013e32834cd45b.

Molecular PET imaging in multicenter Alzheimer's therapeutic trials: current trends and implementation strategies

Seibyl J, Zubal IG, Jennings D, Marek K, Doraiswamy PM.

Expert Rev Neurother. 2011 Dec;11(12):1783-93. doi: 10.1586/ern.11.168.

Alzheimer disease biomarkers are associated with body mass index

Vidoni ED, Townley RA, Honea RA, Burns JM; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2011 Nov 22;77(21):1913-20. doi: 10.1212/WNL.0b013e318238eec1.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias